ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Rates of incidental prostate cancer following HoLEP Can it be predicted preoperatively?
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to identify preoperative predictors of incidental prostate cancer (iPCa) in patients undergoing holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH) and to evaluate subsequent followup strategies.
methodsWe retrospectively analyzed 571 patients who underwent HoLEP by a single surgeon between 2020 and 2024 and who attended at least one postoperative followup visit at our tertiary center. Demographic features, preoperative clinical parameters, and pathologic findings were recorded. Treatment decisions following the diagnosis of iPCa were also analyzed. To reduce baseline imbalances and ensure analytical rigor, propensity score matching was performed.
resultsThe incidence of iPCa was 7.81%. After propensity score matching, elevated preoperative prostate-specfic antigen (PSA) density was significantly associated with the presence of iPCa (odds ratio [OR] 1.095, 95% confidence interval [CI] 1.04-1.16, p=0.01). In a separate analysis, older age (OR 1.11, 95% CI 1.03-1.19, p=0.005), higher total PSA (OR 1.13, 95% CI 1.04-1.22, p= 0.03), and higher PSA density (0.24 vs. 0.04, p<0.001) were identified as clinically significant factors distinguishing the clinically significant prostate cancer group from the clinically insignificant prostate cancer plus benign group.
conclusionsPSA density was identified as an independent preoperative predictor of incidental prostate cancer following HoLEP, whereas older age, higher total PSA, and elevated PSA density were found to be clinically significant factors associated with clinically significant cases. In older patients with high PSA density, further evaluation for possible prostate cancer may be considered before HoLEP, particularly if the detection of clinically significant disease would alter the decision to proceed with surgery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.